Importantly, Unigene restructured its loan obligations earlier this year in May 2007 and eliminated its "going concern" status. The loans are primarily from officers and total approximately $16 million. They are now recast over eight years at 9 percent interest with no payments due (interest will accrue) for the first three years and no prepayment penalties.
With Fortical gaining market share, an advancing pipeline targeting large markets, a near-term positive bottom line, and huge upside potential, we believe that Unigene represents a significant opportunity for investors.
UGNE currently has only one product on the market. Any changes in market demand, USL's ability to market the product, any regulatory changes, or any delays in production would have a significant negative impact on the Company.
UGNE has products in its pipeline in various stages of development; however, Unigene may never develop another product that receives regulatory approval.
Unigene has incurred significant operating losses since its inception. The most recent quarter (September 2007) showed an accumulated deficit of $121.6 million. UGNE is dependent on partnerships and collaborations in the development of its pipeline. The Company's inability to establish new partnerships and to maintain current corporate partnerships and licensing arrangements would negatively impact the progress of the Company.
The pharmaceutical industry is extremely competitive in general, and with the aging population swelling the ranks of osteoporosis sufferers, competition in this market has heated up. Unigene competes with large companies with established products and other therapies that may emerge and displace calcitonin.
|SOURCE Unigene Laboratories Inc.|
Copyright©2008 PR Newswire.
All rights reserved